mebufotenin

Tourmaline Bio's antibody drug pacibekitug demonstrated significant reduction in cardiovascular risk biomarkers compared to placebo in Phase 2 trials, but shares fell 18% as investors question its competitive edge against Novo Nordisk's offering.

GH Research's inhaled mebufotenin (GH001) demonstrated significant efficacy in a Phase 2b trial for treatment-resistant depression, achieving a 15.5-point reduction in MADRS scores compared to placebo (p<0.0001).

Shionogi & Co. plans to acquire Japan Tobacco's pharmaceutical subsidiaries Torii Pharmaceutical and Akros Pharma for ¥160 billion ($1.1 billion) to strengthen its global R&D capabilities.

atai Life Sciences has dosed the first patient in its Phase 2 Elumina trial of VLS-01 (buccal film DMT) for treatment-resistant depression, with topline data expected in Q1 2026.

MindMed maintains robust financial health with $273.7M cash reserves as of December 2023, ensuring operational funding through 2027 despite reporting Q4 loss of $0.41 per share.